Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia

被引:1
|
作者
Ansstas, George [1 ]
Vij, Ravi [1 ]
机构
[1] Washington Univ, Sch Med, Sect Bone Marrow Transplant & Leukemia, St Louis, MO 63110 USA
关键词
Chronic myeloid leukemia; chronic myelogenous leukemia; progression-free survival; event-free survival; disease progression; BCR-ABL inhibitor; DIAGNOSED CHRONIC-PHASE; COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR THERAPY; ALPHA PLUS CYTARABINE; MOLECULAR RESPONSES; FOLLOW-UP; IMATINIB; INTERFERON; DASATINIB;
D O I
10.3109/10428194.2011.653786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standardized definitions of response and outcome are useful to evaluate study data, facilitate treatment guideline adherence and aid clinical decision-making. Although definitions of response in chronic myeloid leukemia (CML) have been standardized, definitions of disease progression have not been standardized, despite widespread adoption of the term to reflect development of advanced disease. This article reviews definitions of response and disease progression used for progression-free survival and event-free survival in key CML studies and implications for interpreting patient response. It is proposed that adherence to definitions of progression from the European LeukmiaNet may aid future research and therapeutic decision-making.
引用
收藏
页码:1273 / 1281
页数:9
相关论文
共 50 条
  • [41] Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
    van de Velde, Helgi J. K.
    Liu, Xiangyang
    Chen, Gang
    Cakana, Andrew
    Deraedt, William
    Bayssas, Martine
    HAEMATOLOGICA, 2007, 92 (10) : 1399 - 1406
  • [42] Serum beta 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma
    Hallek, M
    Wanders, L
    Ostwald, M
    Busch, R
    Senekowitsch, R
    Stern, S
    Schick, HD
    KuhnHallek, I
    Emmerich, B
    LEUKEMIA & LYMPHOMA, 1996, 22 (5-6) : 439 - 447
  • [43] Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
    Freise, Kevin J.
    Jones, Aksana K.
    Menon, Rajeev M.
    Verdugo, Maria E.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 679 - 684
  • [44] Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer
    Garside, Jamie
    Shen, Qin
    Westermayer, Bernd
    van de Ven, Michiel
    Kroep, Sonja
    Chirikov, Viktor
    Juhasz-Boess, Ingolf
    CLINICAL THERAPEUTICS, 2023, 45 (10) : 983 - 990
  • [45] Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer
    Shimokawa, M.
    Ohki, M.
    Kaku, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2015, 36 (04) : 370 - 375
  • [46] Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
    Solomon, B. J.
    Loong, H. H.
    Summers, Y.
    Thomas, Z. M.
    French, P.
    Lin, B. K.
    Sashegyi, A.
    Wolf, J.
    Yang, J. C-H
    Drilon, A.
    ESMO OPEN, 2022, 7 (02)
  • [47] Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
    Tate, Shinichi
    Nishikimi, Kyoko
    Matsuoka, Ayumu
    Otsuka, Satoyo
    Shiko, Yuki
    Ozawa, Yoshihito
    Kawasaki, Yohei
    Shozu, Makio
    CANCERS, 2021, 13 (13)
  • [48] Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
    Foster, Nathan R.
    Renfro, Lindsay A.
    Schild, Steven E.
    Redman, Mary W.
    Wang, Xiaofei F.
    Dahlberg, Suzanne E.
    Ding, Keyue
    Bradbury, Penelope A.
    Ramalingam, Suresh S.
    Gandara, David R.
    Shibata, Taro
    Saijo, Nagahiro
    Vokes, Everett E.
    Adjei, Alex A.
    Mandrekar, Sumithra J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (07) : 1099 - 1106
  • [49] Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact
    Rayson, Daniel
    Lutes, Sarah
    Walsh, Gordon
    Sellon, Marlene
    Colwell, Bruce
    Dorreen, Mark
    Drucker, Arik
    Jeyakumar, Alwin
    Younis, Tallal
    BREAST JOURNAL, 2014, 20 (04) : 408 - 413
  • [50] A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study
    Hu, Shi-wei
    Yang, Xiu-di
    Wu, Di-jiong
    Wang, Yi
    Zhu, Xiao-qiong
    Feng, Wei-ying
    Qian, Hong-lan
    Lu, Ying
    Chen, Li-li
    Cao, Li-hong
    Le, Jing
    Zhang, Li
    Shao, Yan-ping
    Liu, Li-rong
    Tian, Guo-yan
    Zhou, Hui
    Chen, Yu
    Yin, Xiu-feng
    Feng, Xiao-ning
    Huang, Li
    Zhang, Kai-feng
    Xia, Yong-ming
    Xu, Lin-juan
    Zhang, Hui-qi
    Zhang, Gang
    Jia, Yong-qing
    Zhou, Xiu-jie
    Wu, Gong-qiang
    Tu, Jin-ming
    Zhu, Feng
    Zhang, Yue-feng
    Yao, Guo-li
    Zhu, Jing-jing
    Tong, Hong-yan
    Jin, Jie
    Huang, Jian
    SCIENTIFIC REPORTS, 2025, 15 (01):